Meeting
2012 ASCO Annual Meeting
Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.
Authors
Karim Fizazi
Institut Gustave Roussy, Villejuif, France
Karim Fizazi , Christophe Massard , Matthew Raymond Smith , Michael E. Rader , Janet Elizabeth Brown , Piotr Milecki , Neal D. Shore , Stephane Oudard , Lawrence Ivan Karsh , Michael Anthony Carducci , Ronaldo Damião , Huei Wang , Carsten Dietrich Goessl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00321620
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4642)
DOI
10.1200/jco.2012.30.15_suppl.4642
Abstract #
4642
Poster Bd #
10A
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.
First Author: Edoardo Francini
Poster
2018 ASCO Annual Meeting
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.
First Author: Li Zhang
Poster
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
First Author: Jordan Bauman
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell